Alphatec Q1 2026 slides: volume surge masks revenue miss, EOS struggles

Alphatec Holdings Inc. (NASDAQ:ATEC) presented its first quarter 2026 financial results on May 5, revealing a complex picture of robust surgical procedure growth tempered by execution challenges and a revenue shortfall. The spine-focused medical device company reported total revenue of $192 million, missing analyst expectations of $197.63 million by approximately 2.8%, leading to a 0.68% decline in aftermarket trading to $10.26 per share.

Despite the revenue miss, the company’s presentation emphasized significant progress in procedural volume adoption and profitability metrics, with adjusted EBITDA nearly doubling year-over-year. The stock has faced considerable pressure in 2026, down 51% year-to-date, as investors weigh the company’s long-term growth strategy against near-term execution hurdles.

The company’s first quarter demonstrated the divergence between volume growth and revenue realization. As illustrated in the quarterly highlights, Alphatec achieved industry-leading procedural metrics while navigating revenue headwinds.

Surgical revenue grew 17% year-over-year to $178 million, driven by exceptional case volume growth of 21% and net new surgeon additions of 23%. This surgeon adoption momentum reflects the company’s strategy of building procedural loyalty through clinical differentiation, particularly in lateral spine procedures.

However, revenue per case declined 3% year-over-year, with U.S. procedures down 2% and an additional 130 basis point headwind from international case mix. This per-case pressure, combined with challenges in the EOS imaging business, contributed to the overall revenue shortfall.

The detailed revenue performance breakdown reveals the growth dynamics and headwinds affecting the quarter.

The EOS imaging segment presented a significant challenge, with revenue declining 18% to $14 million. Management attributed this decline to execution-related issues around installation timing and system placements, rather than fundamental demand weakness. CEO Pat Miles acknowledged these challenges during the earnings call, noting that corrective actions are underway.

Despite the revenue miss, Alphatec demonstrated substantial progress toward sustainable profitability, with operating leverage improvements across the income statement. The company’s non-GAAP profit and loss highlights show disciplined expense management translating revenue growth into margin expansion.

Gross margin improved 120 basis points to 71.6%, driven by asset efficiency gains and favorable product mix. More notably, operating expenses as a percentage of revenue declined 480 basis points to 68.7%, with sales, general and administrative expenses improving 420 basis points despite a 17% increase in surgical revenue.

This operating discipline enabled adjusted EBITDA to reach $21 million, representing 97% year-over-year growth and a margin of 10.8%—up 460 basis points from the prior year. The adjusted EBITDA drop-through rate of 45% demonstrates the company’s ability to convert incremental revenue into profitability as it scales.

Operating profit margin turned positive at 2.9%, a 600 basis point improvement year-over-year, marking a significant inflection point in the company’s path to sustained profitability.

Alphatec strengthened its financial foundation through a significant debt refinancing that will reduce interest expenses and extend maturities. The company’s proforma balance sheet transformation illustrates the strategic benefits of the new credit facility.

The new term loan and revolving credit facility, anchored by JP Morgan and TD Cowen, consolidates two legacy facilities into a single $300 million arrangement. The refinancing reduces the interest rate from SOFR plus 575 basis points to SOFR plus 275 basis points, saving more than $6 million annually and $35 million over the life of the loan. The maturity extension to May 2031 provides greater financial flexibility to execute the company’s growth strategy.

Free cash flow usage of $11 million in the first quarter came in at the favorable end of management’s $10-15 million guidance range, with trailing twelve-month free cash flow improving to positive $7 million. The company ended the quarter with $140 million in cash and $60 million in available borrowing capacity, providing $200 million in total liquidity.

Alphatec’s presentation emphasized its "Organic Innovation Machine" as a key differentiator in the competitive spine market. The company’s product ecosystem demonstrates breadth across cervical, anterior, and posterior procedures.

The lateral procedure platform continues to serve as the foundation for surgeon adoption and portfolio expansion. As surgeon confidence builds through lateral procedures, utilization expands across the company’s entire procedural portfolio. The surgeon adoption data illustrates this strategic flywheel effect.

Surgeon users of Alphatec’s lateral procedures have grown from under 400 in 2018 to over 1,600 in 2025, while average cases per surgeon have increased across all procedural lines. This expanding utilization demonstrates the company’s ability to deepen relationships and capture greater wallet share as surgeons gain confidence in the platform.

The EOS Insight platform represents a critical long-term strategic asset, converting imaging access into procedural planning advantage and data moats. The five-step strategy outlines how EOS installations create compounding value.

Established ATEC users who adopt EOS Insight demonstrate 30% average revenue growth, with the planning software becoming integral to pre-operative workflow. Patient-specific rods manufactured from EOS data lock in hardware pull-through while building a proprietary database of structured imaging and longitudinal outcomes that can inform future AI capabilities.

The EOS Insight platform continues advancing with proprietary algorithms and measurements that differentiate the offering beyond imaging alone.

New capabilities including the ODHA 3D parameter for spinal alignment, patient-specific pelvis modeling, and reciprocal change prediction algorithms provide surgeons with planning tools unavailable from competitors. This technological moat positions EOS Insight as a data advantage rather than simply an imaging modality.

The Valence navigation system is gaining clinical traction, with early surgeon feedback highlighting procedural integration and workflow efficiency. Authentic operating room images from the presentation show surgical teams actively utilizing the system during procedures, validating the commercial readiness and clinical acceptance of the technology.

Management maintained its full-year 2026 revenue outlook while adjusting expectations for the EOS business. The revenue guidance breakdown shows continued confidence in surgical growth offsetting imaging headwinds.

The company projects total revenue of $882 million for fiscal 2026, representing 15% year-over-year growth. Surgical revenue is expected to reach $805 million with 17% growth, while EOS revenue is projected at $77 million with flat year-over-year performance—a reduction from prior expectations that reflects first quarter execution challenges.

The comprehensive financial outlook emphasizes three strategic pillars: growth leadership, powerful leverage, and free cash flow generation.

Adjusted EBITDA guidance of $134 million implies a 15% margin, representing continued operating leverage expansion. Free cash flow of $20 million would mark a significant inflection from historical cash consumption, enabling self-funded growth investments.

Alphatec’s presentation reinforced its differentiated positioning in the spine market based on procedural focus, lateral leadership, and data advantages. The strategic summary highlights five core strengths the company believes create competitive separation.

The company’s 100% spine focus contrasts with larger diversified competitors like Medtronic and Globus Medical, enabling dedicated innovation resources and surgeon relationships. Leadership in lateral procedures, particularly with the Valence navigation system, provides a growth engine as this approach gains adoption. The deformity segment, enhanced by EOS Insight, represents another high-growth category where Alphatec sees opportunity for share gains.

Management emphasized that foundational infrastructure investments position the company for long-term scalability, with the recent profitability inflection validating the strategy. However, near-term execution challenges, particularly in the EOS business, and revenue per case pressure represent risks to the growth trajectory.

The company faces competition from well-capitalized incumbents and must continue demonstrating that its procedural approach and technology differentiation translate into sustainable market share gains. With the stock trading near 52-week lows at $10.33, investors appear skeptical about the pace of the turnaround despite improving profitability metrics.

As Alphatec navigates the balance between volume growth and revenue realization, the coming quarters will test whether the company’s innovation pipeline and surgeon adoption momentum can overcome execution headwinds and deliver on its full-year commitments.

Full presentation:

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.